COMMUNIQUÉS West-GlobeNewswire

Humanigen CEO to Present at NobleCon14, BIO CEO Investor Conferences

25/01/2018 - 14:00

BRISBANE, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for immunotherapy and oncology [...]

Actinium Pharmaceuticals Issues Letter to Investors Providing Company Update and Outlook for 2018

25/01/2018 - 14:00

Strong finish to 2017 sets stage for series of value enhancing milestones in 2018 NEW YORK, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced [...]

ConforMIS Announces Pricing of Public Offering of Common Stock

25/01/2018 - 14:00

BILLERICA, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ: CFMS ), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell [...]

HempAmericana Begins Construction on CBD Oil Extraction Facility; The largest CBD Oil Extraction Machine in the Northeast is weeks away from full production

25/01/2018 - 14:00

NEW YORK, Jan. 25, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- HempAmericana, Inc. (OTC:HMPQ) (“HempAmericana” or the “Company”) is excited to update the Company’s progress on what is poised to become one of the most [...]

Easton Pharmaceuticals Announces The Signing Of Closed Sub-Distribution Agreement for Product VS-Sense

25/01/2018 - 14:00

Agreement Terms Include Several Up-Front Cash Payments Based On Milestones And A Time Limited Recurring Royalty Payment on Each Product Sold TORONTO, ON, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Easton Pharmaceuticals, Inc. ( [...]

XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus

25/01/2018 - 14:00

AUSTIN, Texas, Jan. 25, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT ) announced today the publication of “ A Natural Human Monoclonal Antibody Targeting Staphylococcus Protein A Protects Against Staphylococcus [...]

Five Prime Announces Pricing of Upsized Public Offering of Common Stock

25/01/2018 - 14:00

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq: FPRX ), announced today the pricing of an underwritten public offering of 5,128,205 shares of its common stock at a [...]

Achaogen Announces New Employment Inducement Grants

25/01/2018 - 14:00

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO ), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram- [...]

Interpace Diagnostics to Present at NobleCon14 on January 29

25/01/2018 - 14:00

PARSIPPANY, N.J. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- INTERPACE DIAGNOSTICS GROUP, INC.(NASDAQ: IDXG ), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests [...]

Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock

25/01/2018 - 13:45

SAN CARLOS, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA ), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) [...]

ProMIS Neurosciences Issues White Paper Entitled: “Not All Amyloid Beta Therapeutics Are Created Equal”

25/01/2018 - 13:30

ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Improved Therapeutic Potency versus other Amyloid Beta-Directed Antibodies ………….. … TORONTO and CAMBRIDGE, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE [...]

Provant Health to Present at the NobleCon14 on January 30, 2018

25/01/2018 - 13:30

OLATHE, Kan., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Hooper Holmes, Inc. d/b/a Provant Health (OTCQX:HPHW), the largest publicly-traded, pure-play well-being leader in workplace population health and clinical research [...]

DLT Resolution to acquire 80% of fast growing Canadian start-up A.J.D. Data Services Ltd.

25/01/2018 - 13:30

Las Vegas, NV, Jan. 25, 2018 (GLOBE NEWSWIRE) -- DLT Resolution Inc. (OTC: DLTI), a blockchain technology and data services company providing distributed ledger technology that currently services the healthcare and [...]

BGI Increases Long-Read Sequencing Capacity with Purchase of 10 PacBio Sequel Systems

25/01/2018 - 13:30

MENLO PARK, California and SHENZHEN, China, Jan. 25, 2018 (GLOBE NEWSWIRE) -- BGI, one of the world’s largest genomics organizations, and Pacific Biosciences of California, Inc. (Nasdaq: PACB), the leader in long-read [...]

Meridian Bioscience Reports First Quarter 2018 Operating Results, Declares Regular First Quarter Cash Dividend, and Reaffirms Fiscal 2018 Guidance

25/01/2018 - 13:15

CINCINNATI, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ) today: GENERAL HIGHLIGHTS reported first quarter net revenues of $52.3 million, an increase of 12% from the same period of the [...]

Summit Therapeutics plc : Interim 24-Week Data from PhaseOut DMD

25/01/2018 - 13:06

Summit Therapeutics plc ('Summit', or 'the Company') EZUTROMID SIGNIFICANTLY REDUCED MUSCLE DAMAGE IN DMD PATIENTS IN 24-WEEK INTERIM DATA FROM SUMMIT'S PhaseOut DMD CLINICAL TRIAL Increase in Utrophin Protein [...]

Sonoma Pharmaceuticals Announces Fiscal Third Quarter 2018 Financial Results and Conference Call

25/01/2018 - 13:05

PETALUMA, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW) today announced that financial results for its fiscal third quarter 2018, ended December 31, 2017, will be [...]

Myriad to Announce Fiscal Second-Quarter 2018 Financial Results on February 6, 2018

25/01/2018 - 13:05

SALT LAKE CITY, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN ) today announced that it will hold its fiscal second-quarter 2018 sales and earnings conference call with investors and analysts at [...]

Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial

25/01/2018 - 13:00

Increase in Utrophin Protein Expression Observed Summit Accelerating Preparations for Pivotal Clinical Trial Ezutromid is a Potential Disease-Modifying Treatment for the Entire DMD Patient Population Conference Call [...]